Moreover, the recent results of the phase II Destiny-PanTumor02 trial entered the use of trastuzumab-deruxtecan in the treatment armamentarium in recurrent HER2 (+) endometrial cancer [153]. The gene discussed is ERBB2; the disease is endometrial cancer.